Clinical trial · no report yet · Phase 3
LIBRETTO-432
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
- NCT04819100 ↗
- Active not recruiting
- Eli Lilly and Company
- 124 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 79 | |
| YouTube | 22 | |
| Podcasts | 18 | |
| X videos | 5 |
The trial
ClinicalTrials.gov- Official title
- LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Selpercatinib; Placebo
- Arms
- Selpercatinib · Experimental
- Placebo · Placebo comparator
- Enrollment
- 152 (estimated)
- Primary outcomes
- Event-Free Survival (EFS)
- Sponsor
- Eli Lilly and Company with Loxo Oncology, Inc.
- Start
- Dec 20, 2021
- Primary completion
- Jan 12, 2026
- Results posted
- No
- Registry record
- NCT04819100 · updated Mar 4, 2026
Publications
linked from the registry- Wu YL, Hochmair M, Yang Y, Yang XN, Tsuboi M, Paz-Ares L, Yang JC, Wu L, Kim HR, Rieke DT, Johnson M, Besse B, Sharma N, Maeda P, Peterson P, Lin BK, Frimodt-Moller B, Goldman J, Drilon A; LIBRETTO-432 Trial Investigators. Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2026 May 31. doi: 10.1056/NEJMoa2602628. Online ahead of print. PubMed 42223087
- Tsuboi M, Goldman JW, Wu YL, Johnson ML, Paz-Ares L, Yang JC, Besse B, Su W, Chao BH, Drilon A. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer. Future Oncol. 2022 Sep;18(28):3133-3141. doi: 10.2217/fon-2022-0656. Epub 2022 Aug 11. PubMed 35950566